HomeAIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
Previous close
$0.21
Day range
$0.21 - $0.23
Year range
$0.16 - $0.62
Market cap
13.50M USD
Avg Volume
717.94K
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 35.00K | -23.91% |
Operating expense | 4.52M | -44.74% |
Net income | -3.70M | 52.66% |
Net profit margin | -10.57K | 37.78% |
Earnings per share | -0.07 | 57.39% |
EBITDA | -4.43M | 45.38% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 7.20M | -67.89% |
Total assets | 13.59M | -51.23% |
Total liabilities | 10.68M | 103.00% |
Total equity | 2.91M | — |
Shares outstanding | 63.71M | — |
Price to book | 4.28 | — |
Return on assets | -76.60% | — |
Return on capital | -142.29% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -3.70M | 52.66% |
Cash from operations | -3.11M | 45.16% |
Cash from investing | 334.00K | 199.40% |
Cash from financing | 137.00K | -41.20% |
Net change in cash | -2.64M | 54.30% |
Free cash flow | -2.11M | 34.80% |
About
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Founded
1966
Headquarters
Website
Employees
27
